CA
JAZZ icon

CapWealth Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

CapWealth Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-100
Closed -$16K – 191
2014
Q3 		$16K Hold
100
– – ﹤0.01% 202
2014
Q2 		$15K Buy
+100
New +$13.9K ﹤0.01% 211

Other funds holding JAZZ

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
WBC
Westpac Banking Corp Sydney, Australia $1.44B AUM 28.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CapWealth Advisors's JAZZ Position: Q4 2014 in Review

CapWealth Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2014, closing a stake of 100 shares — an estimated $16K sold.

CapWealth Advisors first reported a position in JAZZ in Q2 2014 and held it in 2 quarters. The position peaked at $16K in Q3 2014. 357 funds tracked by Wall St. Rank hold JAZZ as of Q4 2014.

  • CapWealth Advisors reported no remaining Jazz Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • CapWealth Advisors sold 100 Jazz Pharmaceuticals shares in Q4 2014, an estimated $16K.
  • CapWealth Advisors first reported a position in Jazz Pharmaceuticals in Q2 2014 and held it in 2 quarters.
  • CapWealth Advisors's Jazz Pharmaceuticals position peaked at $16K in Q3 2014.
  • 357 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2014.

Based on CapWealth Advisors's 13F filing for Q4 2014, filed 11 Feb 2015.